Hospital Partnership Programme
A structured relationship covering molecular decision support, referral pathways and joint scientific work.
Hospitals
Precision oncology for hospitals
Molecular decision-making capability is expensive to build from scratch and difficult to sustain at low case volume. Partnership offers an alternative route to it.
Offerings
What a partnership can cover
Molecular decision-making capability is expensive to build from scratch and hard to sustain at low case volume. These are routes to it that do not require building it alone.
Tele-Molecular Tumour Board
Remote molecular tumour board participation for hospitals without an in-house board.
Joint Clinics
Combined clinics bringing molecular interpretation alongside the treating clinical team.
Precision Oncology Referral Pathway
A defined route for complex cases to reach molecular review, with agreed criteria and turnaround expectations.
Molecular Decision Support
Structured interpretation support for molecular reports generated within the institution.
White-Label Tumour Board
Molecular tumour board infrastructure operated under the hospital’s own identity.
Clinical SOP Development
Development of standard operating procedures for molecular testing, interpretation and reporting.
Research Collaboration
Joint research programmes built on the institution’s clinical and molecular data.
Trial Collaboration
Collaboration on trial feasibility, molecular identification pathways and recruitment strategy.
Brand boundaries. Institutional partnerships may involve KPCIRC as the clinical and institutional entity, and are distinct from Dr. Kwatra's individual professional engagements. Which entity is contracting is agreed explicitly at the outset.
Discuss